Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Journal of Clinical Lipidology
|
December 28, 2020
Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers
Anders Hovland, Ingunn Narverud, Linn Kristin Lie Øyri, et al.
European Heart Journal
|
September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
John J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Journal of Diabetes Research
|
October 21, 2024
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
Gisle Langslet, Thomas Nyström, Dorte Vistisen, et al.
The New England Journal of Medicine
|
March 17, 2015
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
Jennifer G Robinson, Michel Farnier, Michel Krempf, et al.
Lancet (London, England)
|
October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J Raal, Evan A Stein, Robert Dufour, et al.
Journal of Clinical Lipidology
|
December 22, 2015
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
Circulation
|
June 9, 2017
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)
Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
Cardiovascular Diabetology
|
August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Diabetes & Metabolism
|
January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Avraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
European Journal of Human Genetics : EJHG
|
June 12, 2014
Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach
Jorie Versmissen, Daniëlla M Oosterveer, Mojgan Yazdanpanah, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Journal of Clinical Lipidology
|
December 28, 2020
Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers
Anders Hovland, Ingunn Narverud, Linn Kristin Lie Øyri, et al.
European Heart Journal
|
September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
John J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Journal of Diabetes Research
|
October 21, 2024
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
Gisle Langslet, Thomas Nyström, Dorte Vistisen, et al.
The New England Journal of Medicine
|
March 17, 2015
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
Jennifer G Robinson, Michel Farnier, Michel Krempf, et al.
Lancet (London, England)
|
October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J Raal, Evan A Stein, Robert Dufour, et al.
Journal of Clinical Lipidology
|
December 22, 2015
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
Circulation
|
June 9, 2017
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)
Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
Cardiovascular Diabetology
|
August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Diabetes & Metabolism
|
January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Avraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
European Journal of Human Genetics : EJHG
|
June 12, 2014
Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach
Jorie Versmissen, Daniëlla M Oosterveer, Mojgan Yazdanpanah, et al.
Page
of 6